New P2Y12 Inhibitors

被引：168

作者：

Cattaneo, Marco ^{[1
]}

机构：

[1] Univ Milan, Osped San Paolo, Unita Med 3, Dipartimento Med Chirurg & Odontoiatria, I-20142 Milan, Italy

来源：

CIRCULATION | 2010年 / 121卷 / 01期

关键词：

acute coronary syndromes; adenosine diphosphate; antiplatelet agents; platelets; PERCUTANEOUS CORONARY INTERVENTION; ORAL ANTIPLATELET THERAPY; RECEPTOR ANTAGONIST; PLATELET INHIBITION; ACTIVE METABOLITE; PHARMACOLOGICAL CHARACTERIZATION; MYOCARDIAL-INFARCTION; CARDIOVASCULAR EVENTS; EFFICIENT GENERATION; DOUBLE-BLIND;

D O I：

10.1161/CIRCULATIONAHA.109.853069

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：171 / 179

页数：9

共 47 条

[1] Approaching an age of reason with antiplatelet therapy [J].

Ajani, Andrew E. ;

Lefkovits, Jeffrey .

LANCET, 2008, 371 (9621) :1315-1316

[2]

[Anonymous], ADP RECEPTORS ANTAGO

[3] Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study [J].

Bonello, Laurent ;

Camoin-Jau, Laurence ;

Arques, Stephane ;

Boyer, Christian ;

Panagides, Dimitri ;

Wittenberg, Olivier ;

Simeoni, Marie-Claude ;

Barragan, Paul ;

Dignat-George, Francoise ;

Paganelli, Franck .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (14) :1404-1411

[4] Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis [J].

Bonello, Laurent ;

Camoin-Jau, Laurence ;

Armero, Sebastien ;

Com, Olivier ;

Arques, Stephane ;

Burignat-Bonello, Caroline ;

Giacomoni, Marie-Paule ;

Bonello, Roland ;

Collet, Frederic ;

Rossi, Philippe ;

Barragan, Paul ;

Dignat-George, Francoise ;

Paganelli, Franck .

AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (01) :5-10

[5] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel [J].

Brandt, J. T. ;

Close, S. L. ;

Iturria, S. J. ;

Payne, C. D. ;

Farid, N. A. ;

Ernest, C. S., II ;

Lachno, D. R. ;

Salazar, D. ;

Winters, K. J. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) :2429-2436

[6] Safety, tolerability, and initial efficacy of AZD6140, the first reversivle oral adenosine diphosphate receptor antagonist, compared with clopidigrel, in patients with non-ST-segment elevation acute coronary syndrome - Primary results of the DISPERSE-2 trial [J].

Cannon, Christopher P. ;

Husted, Steen ;

Harrington, Robert A. ;

Scirica, Benjamin M. ;

Emanuelsson, Hakan ;

Storey, Robert F. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (19) :1844-1851

[7] Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin [J].

Cattaneo, M. ;

Lecchi, A. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (03) :577-582

[8]

Conley P, 2006, BLOOD, V108, p270A

[9] The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function [J].

Dovlatova, N. L. ;

Jakubowski, J. A. ;

Sugidachi, A. ;

Heptinstall, S. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (07) :1153-1159

[10] Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently [J].

Farid, N. A. ;

Payne, C. D. ;

Small, D. S. ;

Winters, K. J. ;

Ernest, C. S., II ;

Brandt, J. T. ;

Darstein, C. ;

Jakubowski, J. A. ;

Salazar, D. E. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) :735-741

← 1 2 3 4 5 →